Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Accounts Payables (2024 - 2026)

Maze Therapeutics' Accounts Payables history spans 3 years, with the latest figure at $4.0 million for Q1 2026.

  • On a quarterly basis, Accounts Payables rose 66.93% to $4.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $4.0 million, a 66.93% increase, with the full-year FY2025 number at $1.8 million, down 7.48% from a year prior.
  • Accounts Payables hit $4.0 million in Q1 2026 for Maze Therapeutics, up from $1.8 million in the prior quarter.
  • Over the last five years, Accounts Payables for MAZE hit a ceiling of $4.0 million in Q1 2026 and a floor of $1.8 million in Q4 2025.
  • Historically, Accounts Payables has averaged $2.8 million across 3 years, with a median of $2.7 million in 2025.
  • Biggest five-year swings in Accounts Payables: decreased 7.48% in 2025 and later skyrocketed 66.93% in 2026.
  • Tracing MAZE's Accounts Payables over 3 years: stood at $1.9 million in 2024, then decreased by 7.48% to $1.8 million in 2025, then soared by 123.69% to $4.0 million in 2026.
  • Business Quant data shows Accounts Payables for MAZE at $4.0 million in Q1 2026, $1.8 million in Q4 2025, and $2.9 million in Q3 2025.